Kevin Bitterman focuses on creating and investing in companies that translate groundbreaking science into innovative medicines.

Kevin serves on the boards of Disc Medicine (NASDAQ: IRON), Judo Bio, Kinaset Therapeutics, Nvelop Therapeutics and Remix Therapeutics. He is board chair at Chroma Medicine and was the founding CEO of Editas Medicine (NASDAQ: EDIT), Morphic Therapeutic (NASDAQ:MORF) and Visterra (acquired by Otsuka). He previously served as a director of Akero Therapeutics (NASDAQ: AKRO), Mariana Oncology (acquired by Novartis), Vedere Bio (acquired by Novartis), and Taris Biomedical (acquired by Johnson & Johnson) among other ventures. Prior to joining Atlas Venture in 2017, Kevin was a partner at Polaris Partners, where he had been a member of the healthcare team since 2004.

Kevin serves as a member of the Harvard Medical School Blavatnik Biomedical Accelerator and BTCA Steering Committees. He is also a member of the Isabella Stuart Gardner Museum Board of Advisors. He received a BA in biology, with highest honors, from Rutgers University before completing his PhD in genetics at Harvard Medical School.

Outside of work Kevin enjoys spending time with his wife and two daughters.  He also enjoys trail running and whiskey, though generally not at the same time.